Pharmacy and Poisons Board

Clinical Trial Applications - Approved: Filter, Search, and view applications

Clear
Extended search...

Page 1 of 7, showing 10 Applications out of 66 total, starting on record 1, ending on 10

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

1.

 ECCT/26/04/02   IGHID 12430/DELIVER-02
    IGHID12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY    		Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research Centre(MUCRC), Eldoret, Kenya (Uasin Gishu county)
2. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county)
  		25-06-2026 View

2.

 ECCT/26/02/07   IMPAACT 2024
    Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV    		Principal Investigator(s)
1. LUCY Chepkurui Koech
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project(KEMRI/WRP)
  		27-08-2026 View

3.

 ECCT/25/11/02   DELIVER-02
    IGHID 12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY    		Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
1. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county)
2. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (MUCRC), ELDORET (Uasin Gishu county)
  		25-06-2026 View

4.

 ECCT/25/08/09   First-in-human (FIH) study
    A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease    		Principal Investigator(s)
1. Dr Lucas Tina Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute [VIBRI] (Kisumu county)
2. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county)
  		17-09-2026 View

5.

 ECCT/25/07/01   FIH Study of CLY-124
    A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease    		Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county)
2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county)
  		18-12-2025 View

6.

 ECCT/25/04/07   Server migration
    Server Migration    		Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
  		30-04-2025 View

7.

 ECCT/25/02/08   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts    		Principal Investigator(s)
1. Valentine Chepkorir Sing’oei
Site(s) in Kenya
1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
  		06-03-2025 View

8.

 ECCT/25/02/07   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts    		Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI-RCTP (Kisumu county)
  		13-03-2025 View

9.

 ECCT/25/02/06   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts    		Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
  		06-03-2025 View

10.

 ECCT/25/02/05   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts    		Principal Investigator(s)
1. Irene Diana Odhiambo
Site(s) in Kenya
1. Victoria Biomedical Research Institute, Kisumu County Referral Hospital (Kisumu county)
  		07-03-2025 View